Potent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks
Preprint
- 27 December 2024
- preprint
- Published by American Chemical Society (ACS) in ChemRxiv
Abstract
This paper reports highly active analogues of clovibactin in which the rare, non-canonical amino acid D-hydroxyasparagine is replaced with the commercially available amino acid D-threonine. Sequential mutation of leucines 2, 7, and 8 to the more hydrophobic homologue cyclohexylalanine dramatically increases the antibiotic activity of D-Thr5-clovibactin. The resulting analogues (D-Cha2,D-Thr5-clovibactin, Cha7,D-Thr5-clovibactin, and Cha8,D-Thr5-clovibactin) are readily prepared by standard peptide synthesis techniques and exhibit excellent activity (≤ 1 μg/mL) against the Gram-positive, drug-resistant pathogens MRSA and VRE.Keywords
All Related Versions
- Version 1, 2024-12-27, ChemRxiv
- Published version: The Journal of Organic Chemistry, 90 (5), 2132.
Funding Information
- National Institute of Allergy and Infectious Diseases (AI168966)
This publication has 4 references indexed in Scilit:
- Structure–Activity Relationship Studies of the Peptide Antibiotic ClovibactinThe Journal of Organic Chemistry, 2024
- An antibiotic from an uncultured bacterium binds to an immutable targetCell, 2023
- Synthesis and Stereochemical Determination of the Peptide Antibiotic Novo29The Journal of Organic Chemistry, 2023
- Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility TestingAntimicrobial Agents and Chemotherapy, 2008